No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Endpoints article about Pfizer and M&A

https://endpts.com/full-steam-ahead-pfizer-goes-bargain-hunting-in-an-age-of-coronavirus-with-a-special-focus-on-cancer-and-rare-diseases/

I don't have the premium subscription, but the media confirms what we suspected around PFE. Hope DM could close both deals so we can move forward with ZCC and RVX.

Full steam ahead, Pfizer goes bargain hunting in an age of coronavirus — with a special focus on cancer and rare diseases

Pfizer made a splash this week with its plans to spend $500 million on Covid-19 research. But the pharma giant isn’t letting a pandemic interfere with the M&A it needs to fulfill its longterm mission.

In fact, the outbreak may even lend them a hand in finding clinical-stage assets for the pipeline — if only the biotech execs and boards they approach fully understand the position they’re in.

Share
New Message
Please login to post a reply